A single immunization with core–shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs

References

• Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res. 2013;99(1):61–67. doi:10.1016/j.antiviral.2013.01.003
   PubMed Web of Science ®Google Scholar
• Muller T, Hassel R, Jago M, et al. Rabies in kudu: revisited. Adv Virus Res. 2022;112:115–173. doi:10.1016/bs.aivir.2022.04.001
   PubMedGoogle Scholar
• Rupprecht CE, Mani RS, Mshelbwala PP, et al. Rabies in the tropics. Curr Trop Med Rep. 2022;9(1):28–39. doi:10.1007/s40475-022-00257-6
   PubMedGoogle Scholar
• Blanton JD, Rupprecht CE. Travel vaccination for rabies. Expert Rev Vaccines. 2008;7(5):613–620. doi:10.1586/14760584.7.5.613
   PubMed Web of Science ®Google Scholar
• Hellgren F, Cagigi A, Arcoverde Cerveira R, et al. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses. Nat Commun. 2023;14(1):3713. doi:10.1038/s41467-023-39421-5
   PubMed Web of Science ®Google Scholar
• Warrell MJ. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Med Infect Dis. 2012;10(1):1–15. doi:10.1016/j.tmaid.2011.12.005
   PubMed Web of Science ®Google Scholar
• Tran CH, Kligerman M, Andrecy LL, et al. Rabies vaccine initiation and adherence among animal-bite patients in Haiti, 2015. PLoS Negl Trop Dis. 2018;12(11):e0006955. doi:10.1371/journal.pntd.0006955
   PubMed Web of Science ®Google Scholar
• Senior K. Global rabies elimination: are we stepping up to the challenge? Lancet Infect Dis. 2012;12(5):366–367. doi:10.1016/s1473-3099(12)70096-8
   PubMed Web of Science ®Google Scholar
• World Health O. Who expert consultation on rabies. Second report. World Health Organ Tech Rep Ser. 2013;(982):1-139, back cover.
   Google Scholar
• Stitz L, Vogel A, Schnee M, et al. A thermostable messenger RNA based vaccine against rabies. Plos Neglect Trop D. 2017;11(12). doi:10.1371/journal.pntd.0006108
   PubMed Web of Science ®Google Scholar
• Fooks AR, Banyard AC, Ertl HCJ. New human rabies vaccines in the pipeline. Vaccine. 2019;37(Suppl 1):A140–A1A5. doi:10.1016/j.vaccine.2018.08.039
   PubMedGoogle Scholar
• Amann R, Rohde J, Wulle U, et al. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. J Virol. 2013;87(3):1618–1630. doi:10.1128/JVI.02470-12
   PubMed Web of Science ®Google Scholar
• Fooks AR, Banyard AC, Horton DL, et al. Current status of rabies and prospects for elimination. Lancet. 2014;384(9951):1389–1399. doi:10.1016/S0140-6736(13)62707-5
   PubMed Web of Science ®Google Scholar
• Zhang NN, Zhang RR, Zhang YF, et al. Rapid development of an updated mRNA vaccine against the SARS-CoV-2 omicron variant. Cell Res. 2022;32(4):401–403. doi:10.1038/s41422-022-00626-w
   PubMed Web of Science ®Google Scholar
• Laczko D, Hogan MJ, Toulmin SA, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53(4):724–732. doi:10.1016/j.immuni.2020.07.019
   PubMed Web of Science ®Google Scholar
• Lederer K, Castano D, Gomez Atria D, et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity. 2020;53(6):1281–1295. doi:10.1016/j.immuni.2020.11.009
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Z, Luo J, et al. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20(1):33. doi:10.1186/s12943-021-01311-z
   PubMed Web of Science ®Google Scholar
• Sahin U, Kariko K, Tureci O. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780. doi:10.1038/nrd4278
   PubMed Web of Science ®Google Scholar
• Pascolo S. The messenger's great message for vaccination. Expert Rev Vaccines. 2015;14(2):153–156. doi:10.1586/14760584.2015.1000871
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279. doi:10.1038/nrd.2017.243
   PubMed Web of Science ®Google Scholar
• Qu L, Yi ZY, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728. doi:10.1016/j.cell.2022.03.044
   PubMed Web of Science ®Google Scholar
• Durymanov M, Reineke J. Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers. Front Pharmacol. 2018: 9. doi:10.3389/fphar.2018.00971
   PubMed Web of Science ®Google Scholar
• Fenton OS, Kauffman KJ, McClellan RL, et al. Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent In vivo mRNA delivery. Adv Mater. 2016;28(15):2939–2943. doi:10.1002/adma.201505822
   PubMed Web of Science ®Google Scholar
• Jackson NAC, Kester KE, Casimiro D, et al. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11. doi:10.1038/s41541-020-0159-8
   PubMed Web of Science ®Google Scholar
• Rui Y, Wilson DR, Tzeng SY, et al. High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA. Sci Adv. 2022;8(1):eabk2855. doi:10.1126/sciadv.abk2855
   PubMed Web of Science ®Google Scholar
• Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345–351. doi:10.1016/j.jconrel.2015.08.007
   PubMed Web of Science ®Google Scholar
• Shi Y, Huang J, Liu Y, et al. Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses. Sci Adv. 2022;8(47):1827. doi:10.1126/sciadv.abo1827
   Web of Science ®Google Scholar
• Di J, Du Z, Wu K, et al. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharm Res. 2022;39(1):105–114. doi:10.1007/s11095-022-03166-5
   PubMed Web of Science ®Google Scholar
• Yang R, Deng Y, Huang BY, et al. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Tar. 2021;6(1). doi:10.1038/s41392-021-00634-z
   Web of Science ®Google Scholar
• Chen J, Ye Z, Huang C, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proc Natl Acad Sci U S A. 2022;119(34):e2207841119. doi:10.1073/pnas.2207841119
   PubMed Web of Science ®Google Scholar
• Persano S, Guevara ML, Li Z, et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017;125:81–89. doi:10.1016/j.biomaterials.2017.02.019
   PubMed Web of Science ®Google Scholar
• Schnee M, Vogel AB, Voss D, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. Plos Neglect Trop D. 2016;10(6). doi:10.1371/journal.pntd.0004746
   PubMed Web of Science ®Google Scholar
• Bai S, Yang T, Zhu C, et al. A single vaccination of nucleoside-modified rabies mRNA vaccine induces prolonged highly protective immune responses in mice. Front Immunol. 2022;13:1099991. doi:10.3389/fimmu.2022.1099991
   PubMed Web of Science ®Google Scholar
• Zhang CG, Tian YL, Chen C, et al. Virus-Like vesicles based on Semliki forest virus-containing rabies virus glycoprotein make a safe and efficacious rabies vaccine candidate in a mouse model. J Virol. 2021;95(20). doi:10.1128/JVI.00790-21
   Web of Science ®Google Scholar
• Ren MS, Zhou JJ, Song ZY, et al. Aptamer and RVG functionalized gold nanorods for targeted photothermal therapy of neurotropic virus infection in the mouse brain. Chem Eng J. 2021: 411. doi:10.1016/j.cej.2021.128557
   Web of Science ®Google Scholar
• Wang ZM, Yuan YM, Chen C, et al. Colloidal manganese salt improves the efficacy of rabies vaccines in mice, cats, and dogs. J Virol. 2021;95(23). doi:10.1128/JVI.01414-21
   Web of Science ®Google Scholar
• Luo ZC, Lv L, Li YY, et al. Dual role of toll-like receptor 7 in the pathogenesis of rabies virus in a mouse model. J Virol. 2020;94(9). doi:10.1128/JVI.00111-20
   Web of Science ®Google Scholar
• Zhang YN, Chen C, Deng CL, et al. A novel rabies vaccine based on infectious propagating particles derived from hybrid VEEV-rabies replicon. Ebiomedicine. 2020: 56. doi:10.1016/j.ebiom.2020.102819
   Web of Science ®Google Scholar
• Liang ML, Wang ZM, Wu CJ, et al. A single dose of recombinant VSV-RABV(G) vaccine provides full protection against RABV challenge. Virol Sin. 2022;37(3):455–458. doi:10.1016/j.virs.2022.02.008
   PubMed Web of Science ®Google Scholar
• Wang Z, Li MM, Zhou M, et al. A novel rabies vaccine expressing CXCL13 enhances humoral immunity by recruiting both T follicular helper and germinal center B cells. J Virol. 2017;91(3). doi:10.1128/JVI.01956-16
   Web of Science ®Google Scholar
• Aldrich C, Leroux-Roels I, Huang KB, et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. Vaccine. 2021;39(8):1310–1318. doi:10.1016/j.vaccine.2020.12.070
   PubMed Web of Science ®Google Scholar
• Andries O, Mc Cafferty S, De Smedt SC, et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015;217:337–344. doi:10.1016/j.jconrel.2015.08.051
   PubMed Web of Science ®Google Scholar
• Kariko K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–1840. doi:10.1038/mt.2008.200
   PubMed Web of Science ®Google Scholar
• Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41(4):529–542. doi:10.1016/j.immuni.2014.10.004
   PubMed Web of Science ®Google Scholar
• Haberman AM, Gonzalez DG, Wong P, et al. Germinal center B cell initiation, GC maturation, and the coevolution of its stromal cell niches. Immunol Rev. 2019;288(1):10–27. doi:10.1111/imr.12731
   PubMed Web of Science ®Google Scholar
• Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012;247:52–63. doi:10.1111/j.1600-065X.2012.01124.x
   PubMed Web of Science ®Google Scholar
• Kroese FGM, Wubbena AS, Seijen HG, et al. Germinal-centers develop oligoclonally. Eur J Immunol. 1987;17(7):1069–1072. doi:10.1002/eji.1830170726
   PubMed Web of Science ®Google Scholar
• McHeyzer-Williams M, Okitsu S, Wang N, et al. Molecular programming of B cell memory. Nat Rev Immunol. 2012;12(1):24–34. doi:10.1038/nri3128
   Web of Science ®Google Scholar
• Prusty BK, Gulve N, Govind S, et al. Active HHV-6 infection of Cerebellar Purkinje cells in mood disorders. Front Microbiol. 2018;9:1955. doi:10.3389/fmicb.2018.01955
   PubMed Web of Science ®Google Scholar
• Abela-Ridder B, Balogh de K, Kessels JA, et al. Global rabies control: the role of international organisations and the global strategic plan to eliminate dog-mediated human rabies. Rev Sci Tech. 2018;37(2):741–749. doi:10.20506/rst.37.2.2837
   PubMed Web of Science ®Google Scholar
• Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines (Basel). 2021;9(2). doi:10.3390/vaccines9020147
   PubMed Web of Science ®Google Scholar
• Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586. doi:10.1016/j.ijpharm.2021.120586
   PubMed Web of Science ®Google Scholar
• Zhang NN, Li XF, Deng YQ, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271–1283. doi:10.1016/j.cell.2020.07.024
   PubMed Web of Science ®Google Scholar
• Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511–1520. doi:10.1016/S0140-6736(17)31665-3
   PubMed Web of Science ®Google Scholar
• Sun SH, Chen Q, Gu HJ, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020;28(1):124–133. doi:10.1016/j.chom.2020.05.020
   PubMed Web of Science ®Google Scholar
• Lutz J, Lazzaro S, Habbeddine M, et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines. 2017;2:29. doi:10.1038/s41541-017-0032-6
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New Engl J Med. 2020;383(25):2427–2438. doi:10.1056/NEJMoa2028436
   PubMed Web of Science ®Google Scholar
• Di JX, Du ZL, Wu KZ, et al. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharm Res-Dordr. 2022;39(1):105–114. doi:10.1007/s11095-022-03166-5
   PubMed Web of Science ®Google Scholar
• Yang R, Deng Y, Huang B, et al. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021;6(1):213. doi:10.1038/s41392-021-00634-z
   PubMed Web of Science ®Google Scholar
• Yang T, Li C, Wang X, et al. Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle. Bioact Mater. 2020;5(4):1053–1061. doi:10.1016/j.bioactmat.2020.07.003
   PubMed Web of Science ®Google Scholar
• Perry LL, Lodmell DL. Role of Cd4 + and Cd8+ T-cells in murine resistance to street rabies virus. J Virol. 1991;65(7):3429–3434. doi:10.1128/jvi.65.7.3429-3434.1991
   PubMed Web of Science ®Google Scholar
• Tantawichien T, Jaijaroensup W, Khawplod P, et al. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4(+) T lymphocyte counts. Clin Infect Dis. 2001;33(10):E122–E1E4. doi:10.1086/324087
   PubMed Web of Science ®Google Scholar
• Aldridge RW, Yavlinsky A, Nguyen V, et al. SARS-CoV-2 antibodies and breakthrough infections in the virus watch cohort. Nat Commun. 2022;13(1):4869. doi:10.1038/s41467-022-32265-5
   PubMed Web of Science ®Google Scholar
• Gupta RK, Topol EJ. COVID-19 vaccine breakthrough infections. Science. 2021;374(6575):1561–1562. doi:10.1126/science.abl8487
   PubMed Web of Science ®Google Scholar
• Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728–1744. doi:10.1016/j.cell.2022.03.044
   PubMed Web of Science ®Google Scholar
• Ai L, Li Y, Zhou L, et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023;9(1):9. doi:10.1038/s41421-022-00517-9
   PubMed Web of Science ®Google Scholar
• Muramatsu H, Lam K, Bajusz C, et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30(5):1941–1951. doi:10.1016/j.ymthe.2022.02.001
   PubMed Web of Science ®Google Scholar